Blog
About

1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Augmentation of milnacipran by risperidone in treatment for major depression.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Milnacipran, one of the serotonin noradrenaline reuptake inhibitors (SNRIs) to which venlafaxine and duloxetine belong, is a new antidepressant that has recently become available in many countries. Despite the advances in pharmacotherapy, almost one third of patients with depressive illness respond inadequately to monotherapy with such an antidepressant. We herein describe five patients with major depression who responded partially, but not fully, to milnacipran alone and remarkably improved with an adjunct of risperidone. In addition, milnacipran plus risperidone was found to be a useful augmentation for treatment-refractory depression in 3 of the 5 patients. The minimum dose of risperidone, 0.5 or 1 mg/d, was efficacious. The time of response after addition of risperidone was within 4 d. Our experience suggests that an augmentation therapy of milnacipran plus risperidone is useful for treating patients with depression who only partially respond to various types of antidepressants and for treatment-refractory depression.

          Related collections

          Author and article information

          Journal
          Int. J. Neuropsychopharmacol.
          The international journal of neuropsychopharmacology
          Cambridge University Press (CUP)
          1461-1457
          1461-1457
          Mar 2004
          : 7
          : 1
          Affiliations
          [1 ] Department of Psychiatry and Neurology, Hamamatsu University School of Medicine, Japan.
          Article
          S146114570300381X
          10.1017/S146114570300381X
          14731310

          Comments

          Comment on this article